重组人血管内皮抑素联合培美曲塞治疗复治进展期非小细胞肺癌的临床观察

目的　观察和比较重组人血管内皮抑素（恩度）联合培美曲塞与单药培美曲塞治疗晚期复治的非小细胞肺癌（ＮＳＣＬＣ）的近期疗效及毒副反应。方法　３２例均已确诊并有远处转移的复治的晚期ＮＳＣＬＣ患者，其中恩度联合培美曲塞组１２例，培美曲塞单药组２０例，按照ＲＥＳＩＳＴ标准每周期评价化疗疗效和ＷＨＯ标准每周期评价毒性。结果　恩度联合培美曲塞组共完成３５个周期，平均２.９个周期。ＲＲ３例（２５.０％），ＣＢＲ９例（７５.０％）。培美曲塞单药组共完成５５个周期，平均２.７个周期。ＲＲ４例（２０.０％），ＣＢＲ１２例（６０.０％）。两组比较，ＲＲ率差异无统计学意义（Ｐ＞０.０５），ＣＢＲ率差异有统计学意义（Ｐ＜０.０５）。毒副反应主要为骨髓抑制、胃肠道反应，均未达到３级及以上，可以耐受。结论　恩度联合培美曲塞治疗复治晚期ＮＳＣＬＣ具有较好的近期疗效，且毒性反应轻，耐受性好，值得临床进一步应用。

Clinical observation of endostar combined with pemetrexed for advanced non-small cell lung cancer

Objective This study is to observe the clinical benefit and safety of endostar combined pemetrexed in patients with advanced retreatment non-small cell lung cancer(NSCLC).Methods Thirty-two advanced retreatment NSCLC patients who had distant metastasis and measurable tumor were confirmed by pathology and cytology,devided into pemetrexed group(20 cases) and endostar combined with pemetrexed group(12 cases).The efficacy of every circle was evaluated by RESIST standard and toxicity of every circle was evaluate...